Advertisement Feature

Filter By:

Article Type
  • CalciMedica, a clinical-stage biopharma company, is developing potentially first-in-class small molecules to combat excessive intracellular calcium levels that drive pathological processes in inflammatory diseases and acute injury, including COVID-19.

    • CalciMedica Inc.
    Advertisement Feature
  • As a government funder, the Korea Drug Development Fund (KDDF) invests in promising selected compounds by taking them through assessment and translating them into cutting-edge science for patient benefits and market opportunities.

    • Korea Drug Development Fund
    Advertisement Feature
  • The city of Phoenix hosts a thriving life-sciences ecosystem that fosters collaboration among industry, education, research and community partners to transform discoveries into health.

    • City of Phoenix Community and Economic Development Department
    Advertisement Feature
  • Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.

    • MetasTx
    Advertisement Feature
  • Enterome is using its unique Mimicry approach coupled with the power of partnering to harness the potential of the gut’s natural tolerance pathway to address allergies and autoimmune diseases.

    • Enterome
    Advertisement Feature
  • Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.

    • Glyscend, Inc.
    Advertisement Feature
  • First Republic Bank’s relationships in the sector help it meet the unique needs of both startups and seasoned life science companies.

    • First Republic Bank
    Advertisement Feature
  • With Exeliom Biosciences’s drug candidate, EXL01, the long-touted immune-modulation potential of a key gut bacterial species is finally reaching patients in the clinic.

    • Exeliom Biosciences
    Advertisement Feature
  • Microbiotica’s platform makes it a leader in precision clinical discovery of novel microbiome-based therapeutics and biomarkers. With the platform validated at scale, and a pipeline of programs, the company is open to collaborations in both therapeutic and biomarker discovery.

    • Microbiotica
    Advertisement Feature
  • Minaris Regenerative Medicine is developing large-scale 3D cell-production processes and optimizing its culture parameters, as well as enabling in-house batch certification, to enable its partners to realize the huge potential of cell therapies.

    • Minaris Regenerative Medicine
    Advertisement Feature
  • Shape Therapeutics is developing next-generation gene-therapy technologies that harness the power of artificial intelligence and RNA editing to repair disease-causing mutations.

    • Shape Therapeutics
    Advertisement Feature
  • Asgard Therapeutics is moving cancer immunotherapy forward with an off-the-shelf direct cell reprogramming platform that turns cancer cells into immunogenic dendritic cells that induce potent anticancer immunity.

    • Asgard Therapeutics AB
    Advertisement Feature
  • Precision BioSciences is transforming drug development for new, potentially first- and best-in-class cell and gene therapies with its proprietary ARCUS gene-editing platform, which is derived from a small, naturally occurring DNA-editing nuclease.

    • Precision BioSciences, Inc
    Advertisement Feature
  • Regenerative medicine company Locate Bio is aiming to transform the musculoskeletal market with its range of therapeutic orthobiologic products.

    • Locate Bio Ltd
    Advertisement Feature
  • With a focus on detecting, intercepting, treating, and ultimately curing cancer, Janssen Oncology is advancing science and solutions in hematologic malignancies and solid tumors through an innovative strategic partnering approach.

    • Janssen Oncology
    Advertisement Feature